

Ref: FOI/GS/ID 7741

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

31 October 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to non-small cell lung cancer (NSCLC).

You asked:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- a. Afatinib*
- b. Alectinib*
- c. Amivantamab*
- d. Atezolizumab monotherapy*
- e. Atezolizumab with chemotherapy*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Dabrafenib with Trametinib*
- k. Durvalumab*
- l. Erlotinib*
- m. Gefitinib*
- n. Lorlatinib*
- o. Mobocertinib*
- p. Nintedanib with Docetaxel*
- q. Nivolumab*
- r. Osimertinib*
- s. Pembrolizumab monotherapy*
- t. Pembrolizumab with chemotherapy*
- u. Pemetrexed with Carboplatin/Cisplatin*
- v. Pralsetinib*
- w. Selpercatinib*

- x. Sotorasib
- y. Tepotinib
- z. Vinorelbine with Carboplatin/Cisplatin
- aa. Any other active systemic anti-cancer therapy (SACT)
- bb. Palliative care only

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- a. Atezolizumab monotherapy
- b. Atezolizumab with chemotherapy
- c. Durvalumab
- d. Nivolumab
- e. Osimertinib
- f. Pembrolizumab (Keytruda) Mono
- g. Pembrolizumab (Keytruda) with Chemotherapy
- h. Tepotinib
- i. Other active systemic anti-cancer therapy (SACT)
- j. Palliative care only

Q3. Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part.

Trust response:

Q1.

- a. 3
- b. 6
- c. 0
- d. 4
- e. 1
- f. 0
- g. 0
- h. 2
- i. 0
- j. 1
- k. 4
- l. 0
- m. 0
- n. 0
- o. 0
- p. 2
- q. 0
- r. 20
- s. 27
- t. 16
- u. 11
- v. 0
- w. 1
- x. 2
- y. 0
- z. 12
- aa. 12

ab. 0

Q2.

a. 2

b. 0

c. 0

d. 0

e. 1

f. 6

g. 1

h. 0

i. 8

j. 0

3. Open to recruitment

GO41854 - Atezolizumab plus Tiragolumab vs Durvalumab in NSCLC (IRAS 279531)

1 patient recruited

In Follow Up

Osimertinib with or without chemotherapy in EGFR positive NSCLC (IRAS 278270)

1 patient in follow up